Lymphatic Filariasis is a key topic under Social Issues for UPSC Civil Services Examination. Key points include: Lymphatic Filariasis (LF), or elephantiasis, is a neglected tropical disease caused by filarial parasites transmitted by mosquitoes.. India faces a significant LF burden, with 345 endemic districts across 20 states/UTs, necessitating large-scale interventions.. The Bi-annual Nationwide Mass Drug Administration (MDA) campaign is a key strategy to eliminate LF by interrupting transmission.. Understanding this topic is essential for both UPSC Prelims and Mains preparation.
Lymphatic Filariasis is a Medium-level topic in UPSC Social Issues. It is tested in both Prelims (factual MCQs) and Mains (analytical answer writing). Previous year UPSC questions have frequently covered aspects of Lymphatic Filariasis, making it essential for comprehensive IAS preparation.
To prepare Lymphatic Filariasis for UPSC: (1) Study the comprehensive notes covering all key concepts on Vaidra. (2) Practice previous year questions on this topic. (3) Connect it with current affairs using daily updates. (4) Revise using key takeaways and mind maps available for Social Issues. (5) Write practice answers linking Lymphatic Filariasis to related GS Paper topics.

Recently, the Union Minister of State for Health and Family Welfare launched the first phase of the Bi-annual Nationwide Mass Drug Administration (MDA) campaign for Lymphatic Filariasis (LF) elimination. This initiative underscores India's commitment to eradicating neglected tropical diseases.
Lymphatic Filariasis (LF), commonly known as elephantiasis, is a debilitating neglected tropical disease (NTD). It is caused by infection with filarial parasites which are transmitted to humans through mosquito bites.
Definition: Lymphatic Filariasis is a parasitic disease caused by thread-like worms that block the lymphatic system, leading to severe swelling and disfigurement, primarily in the limbs and genitals.
In 2021, approximately 882.5 million people across 44 countries lived in areas requiring preventive chemotherapy. This highlights the widespread global burden of Lymphatic Filariasis.
In India, LF remains a serious public health challenge. Currently, there are 345 Lymphatic Filariasis endemic districts spread across 20 states and union territories.
The recently launched Bi-annual Nationwide MDA campaign aims to interrupt disease transmission. It achieves this by providing free preventive medications to residents in affected areas.
MDA Campaign Goal: To check disease transmission by administering preventive medications. The initial phase of the campaign is set to cover 92 districts across 11 states.
While the primary topic is Lymphatic Filariasis, the source material also details aspects of Kala-Azar, another significant neglected tropical disease in India. Control efforts for various vector-borne diseases often share common strategies and programmatic frameworks.
Suspected cases of visceral leishmaniasis, commonly known as Kala-Azar, require immediate medical attention. Diagnosis involves assessing clinical signs combined with specific parasitological or serological tests.
Mortality Rate: If left untreated, Kala-Azar can be fatal in 95% of cases, underscoring the urgency of early intervention.
Effective prevention and control strategies are crucial for reducing the prevalence of Kala-Azar, preventing disabilities, and saving lives.
The Government of India has a long-standing commitment to eliminating Kala-Azar through various programmatic interventions.
National Vector Borne Disease Control Programme (NVBDCP), 2003: This is an umbrella program that oversees the prevention and control of multiple vector-borne diseases, including malaria, lymphatic filariasis, kala-azar, and chikungunya.
Recent initiatives have focused on multi-pronged strategies to combat Kala-Azar effectively.
PKDL is a skin condition that can follow an episode of visceral leishmaniasis (Kala-Azar). It manifests as rashes on the face, arms, and trunk.
Prevalence: PKDL primarily affects regions like Sudan and the Indian subcontinent, with 5-10% of Kala-Azar patients developing this condition.
PKDL may appear 6 months to a year after the completion of Kala-Azar treatment. Importantly, individuals with PKDL can potentially serve as a reservoir, spreading Leishmania parasites.

